BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Complete Data From RegeneRx Biopharmaceuticals, Inc. (RGRX) Phase II Dry Eye Trial Published In Current Issue Of Clinical Ophthalmology 5/22/2015 6:47:17 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015 11:25:22 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Thymosin B4 Has A Major Role In Dermal Burn Wound Healing 5/4/2015 9:04:42 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance For U.S. Patent For Healing And Reversing Heart And Coronary Vessel Damage After A Heart Attack With TB4 4/23/2015 11:05:05 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Meets Key Efficacy Objectives In Phase II Clinical Trial In Patients With Severe Dry Eye Reported In Current Issue Of Cornea 4/1/2015 7:00:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent Acceptance Notice For The Use Of TB4 To Prevent Tissue Damage Associated With Heart Attack And Stroke Treatments 3/26/2015 11:14:09 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015 10:54:15 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture Partner Receives $7.28 Million USD From Korean Government And Venture Fund For U.S. Development Of RGN-259/GBT-201 3/9/2015 7:09:48 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent For Treating And Repairing Heart Damage 2/25/2015 9:15:55 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates Website 2/19/2015 11:49:17 AM
12345678910...